Abstract
The instant thin-layer chromatographic method of determining the radiochemical purity of 99mTc-tetrofosmin recommended by the manufacturer uses a mixture of acetone and dichloromethane (35:65 v/v) as the solvent and a silica gel (SG) strip as the solid phase. Currently, SG strips are not available commercially and an alternative solid phase is needed. The present study reports that silicic acid strips are an appropriate substitute for SG strips for the chromatographic method using the same solvent mixture but mixed in a reverse ratio (65:35 v/v). The 2 methods yielded similar values (within 1 SD) of radiochemical purity for 99mTc-tetrofosmin.
Radiopharmaceuticals for human use must undergo strict quality control measures to ensure patient safety. The tests include radionuclidic purity, pH, ionic strength, chemical purity, and radiochemical purity. For daily 99mTc kit preparations, all tests except radiochemical purity can be accomplished well before the time of reconstitution. These kits are reconstituted daily by the addition of 99mTc-pertechnetate to the kit vial containing a reducing agent such as stannous ion and chelating agents such as diethylenetriaminepentaacetic acid, methylene diphosphonate, and so on. 99mTc7+ is reduced to lower oxidation states by stannous ion (Sn2+), and the reduced 99mTc then binds to the chelating agent to give 99mTc complex. Incomplete reduction and partial binding can lead to the presence of free and reduced 99mTc along with 99mTc complex in the preparation. In water, the reduced 99mTc is hydrolyzed to several species whose composition is not definitely known. In daily preparations of these radiopharmaceuticals, the proportions of these entities can vary and must be determined before administration to patients because the free and hydrolyzed 99mTc obscures the scintigraphic images and exposes the patient to unnecessary radiation. Instant thin-layer chromatography (ITLC) is a quick method of assessing the radiochemical purity of the 99mTc complex and uses a solvent and a solid phase to separate the different components. One can then measure the activity of each component, from which the fractions of free, hydrolyzed, and chelated (bound) 99mTc in the preparation are determined.
The ITLC procedure recommended by the manufacturer (GE Healthcare) for 99mTc-tetrofosmin (Myoview) requires a solvent of a mixture of acetone and dichloromethane (35:65 v/v) and a solid phase of a silica gel (SG) strip (1). Currently, SG strips have been discontinued by the manufacturer and are not available commercially. Also, the method has the disadvantage of a long procedural time and requires experience with the procedure. Two alternative methods have been reported to mitigate the situation. McKay et al. (2) performed the chromatography using Whatman 1 strips and ethyl acetate and obtained radiochemical purity similar to the manufacturer's recommended values. Eggert et al. (3) reported radiochemical purity in agreement with that of the recommended method, using a solvent-saturated pad and a 1:1 chloroform:tetrahydrofuran solvent mixture.
Although these methods are reasonable enough for daily determination of the radiochemical purity of 99mTc-tetrofosmin, in the absence of SG strips we felt the urgency of having an alternative method. After trials with several alternative solid phases and solvents, we found that the silicic acid (SA) strip is an appropriate alternative to the SG strip for ITLC of 99mTc-tetrofosmin using a solvent mixture of acetone and dichloromethane (65:35 v/v, a reverse ratio of the manufacturer's method). The following is a brief description of the method and the results of ITLC separation of the 3 components—free, hydrolyzed, and bound 99mTc—in the 99mTc-tetrofosmin sample.
MATERIALS AND METHODS
After experiments with several solid phases (Whatman 1 and 3 strips) and solvents (acetone, saline, ethyl acetate, 35:65 acetone:dichloromethane) for an appropriate chromatographic method to determine the radiochemical purity of 99mTc-tetrofosmin, we found an optimal method using a mixture of 65:35 acetone:dichloromethane (v/v) as the solvent and an SA strip as the solid phase (Table 1).
The required materials are a mixture of acetone and dichloromethane (65:35 v/v), an approximately 10-cm-long cylindric glass vial of diameter of 2.5 cm, an ITLC SA strip (11 × 1.5 cm), a 1-mL syringe with 25-gauge needle, and a dose calibrator or any suitable counting system. The ratio of solvents in the mixture is in reverse proportion to the ratio used by the manufacturer. The SA strips are commercially available in a precut size of 1.5 × 11 cm (Varian, Inc., and Auburn Biostrips). The solvent mixture was poured into the vial to a depth of about 0.5 cm at the bottom. A small drop (∼10 μL) of the reconstituted 99mTc-tetrofosmin sample was spotted using the 1-mL syringe with 25-gauge needle at 1.0 cm above one end of a strip, and an ink mark was spotted at 1 cm below the other end. The strip was then placed in the cylindric vial so that the sample spot remained above the solvent. When the solvent reached the ink spot, the strip was removed and air dried to determine the distribution of the 3 components along the strip.
As the solvent ascends the strip, the 3 components migrate to different distances on the strip depending on their solubility in the solvent and adsorption on the solid phase. Each component is characterized by a relative front (Rf) value, which is defined as the ratio of distance traveled by the component to the distance traveled by the solvent front from the sample spot (4). After developing the chromatogram, we cut the strip into 8 equal segments between the sample spot and the solvent to establish these Rf values. The activity in each segment was measured in a dose calibrator and plotted in a histogram. A typical chromatogram obtained from a single ITLC method on a 99mTc-tetrofosmin sample using SA and SG strips is shown in Figure 1. The distribution of the activities indicates the bound 99mTc in the middle, free 99mTc at the solvent front, and hydrolyzed 99mTc at the origin, providing the Rf values of the 3 components. Once the average of these values was established from several initial experiments, in subsequent experiments we simply cut the strips around the peaks of the 3 components for convenience and determined the activities of the 3 segments. The cut positions were marked at 1.5 and 7.5 cm from the spot (or 2.5 and 8.5 cm from the bottom) as shown in Figure 2A. The bottom segment contained hydrolyzed 99mTc, and the upper segment free 99mTc, whereas the middle segment, which had the highest activity, represented bound 99mTc. The fraction of bound 99mTc was then calculated as
For comparison, identical chromatographic experiments were performed following the method recommended by the manufacturer in the package insert of 99mTc-tetrofosmin, which uses the solvent mixture of 35:65 acetone and dichloromethane and an SG strip as the solid phase (Table 1). The recommended size of the strip was 2 × 20 cm, which is longer than the current SA strip used. The cut marks, which are different from those in the SA strips, are shown in Figure 2B for comparison.
RESULTS
ITLC was performed on 26 freshly prepared samples of 99mTc-tetrofosmin, and the results for both SG and SA strips are presented in Figure 3 The figure shows a comparison of percentage-bound 99mTc (radiochemical purity) in each individual preparation of 99mTc-tetrofosmin obtained by the manufacturer's method and by our alternative method. The radiochemical purity is more than 90% by either method, and the average value is 96.5% ± 1.13% for the SA strip and 96.3% ± 1.07% for the SG strip. There is no significant difference between the 2 values, which agree well within 1 SD.
Although the Rf value of 99mTc-tetrofosmin with the SG strip as seen in Figure 1 seems to be slightly higher than that with the SA strip, both values overlap in the range of 0.3–0.8. On this basis, we cut the 3 segments on the SA strip at the marks shown in Figure 2B, with the middle segment (2.5–8.5 cm from the bottom) representing the bound fraction. The average Rf values of free, hydrolyzed, and bound 99mTc obtained are in Table 2 and essentially show no difference between the 2 methods.
DISCUSSION
99mTc-tetrofosmin is used in humans for the assessment of myocardial perfusion to distinguish between ischemia and infarction in the heart (5). The high radiochemical purity (>90%) of the radiopharmaceutical is required for better diagnostic detection of myocardial defects and to avoid unnecessary adverse effects and radiation exposure to patients. For convenience and to keep the procedure brief, the ITLC method is commonly used to separate and estimate the different components of a 99mTc-tetrofosmin preparation. After several trial experiments, the SA strip was fortuitously found to offer an excellent alternative to the manufacturer's SG strip for the ITLC analysis of 99mTc-tetrofosmin preparations using a mixture of acetone and dichloromethane (with a reverse volume ratio of 65:35) as the solvent. The average radiochemical purity of 99mTc-tetrofosmin obtained by our method and the manufacturer's method is above 96% and compares well with that of McKay et al. (2) and Eggert et al. (3). However, both reports used different solid phases and solvents in the ITLC method.
The ITLC method described here is quite short, requiring only 3–4 min for the entire procedure. Easy commercial availability of the SA strip and solvents makes the method more acceptable. A caveat is that acetone and dichloromethane are volatile and may be harmful. The adverse effects depend on the extent of exposure and range from such complaints as headache and dizziness at low exposure to liver damage and cancer at high exposure. It is recommended that these chemicals be handled with caution and preferably in a well-ventilated area.
CONCLUSION
In the absence of SG strips, SA strips are an appropriate substitute as the solid phase along with a 65:35 acetone:dichloromethane mixture as the solvent for assessing the radiochemical purity of 99mTc-tetrofosmin. This alternative method will serve well for all commercial nuclear pharmacies, as well as for individual institutions that prepare 99mTc-tetrofosmin daily.
Acknowledgments
This work was presented in part at the annual meeting of the Society of Nuclear Medicine in Salt Lake City in 2010.
REFERENCES
- Received for publication August 2, 2010.
- Accepted for publication October 1, 2010.